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Hypertension is a major risk factor for cardiovascular disease, and 
has been associated with two-thirds of strokes and almost half of 
ischaemic heart disease cases globally.[1] High blood pressure (BP) 
was the foremost cause of death worldwide in 2008, responsible for 
13 - 14% of global mortality or about 7.5 million deaths.[2]
In South Africa (SA) during the year 2000, 46 888 deaths or 
9% of all deaths were attributable to this treatable condition.[3] 
Hypertension is also a leading cause of heart failure and chronic 
kidney disease both locally and globally. Achieving optimal BP 
control in hypertensive patients remains an idealistic goal, with a 
population survey in SA in 1998 estimating control at 10% for men 
and 18% for women.[4]
It appears that the burden of hypertension has increased expon-
entially over the past decade. A national household survey in 2010 
(the National Income Dynamics Study) measured a prevalence of 
hypertension of >40% in adults aged >25 years.[5] Only 35.7% of 
individuals with hypertension were on treatment, and of these only 
36.4% were controlled.
In another population survey (World Health Organization Study 
on Global Aging and Adult Health, 2007[6]), compared with five other 
countries SA had the highest prevalence of hypertension (77.9%) 
in individuals aged >50 years. Resistant hypertension is associated 
with poor outcomes and appears to be a particular problem in the 
uninsured population.[7]
There are few published data on the control of hypertension and 
the profiles of patients seen at tertiary-level hypertension clinics in 
SA. In a cohort derived from the Oslo Renal Denervation Study, 
83 patients were referred to a tertiary-level hospital for work-up of 
apparent treatment-resistant hypertension;[8] of these, 53 did not have 
true resistant hypertension, and the main reasons for this finding 
were poor drug adherence (32%), secondary hypertension (30%) and 
white-coat hypertension (15%).
We therefore conducted a prospective study of patients referred 
to and followed up at a tertiary-level hypertension clinic at Groote 
Schuur Hospital, Cape Town, SA.
Objectives
To assess the following in all patients referred to our specialist 
hypertension clinic: (i) BP control and target organ damage (TOD); 
(ii) whether age, gender, body mass index (BMI), and uric acid 
and total cholesterol levels were independently associated with 
uncon trolled BP; and (iii) the prevalences of white-coat, apparent 
treatment-resistant and secondary hypertension.
Methods
The study was a 12-month prospective, descriptive, case-control 
study. It was conducted at Groote Schuur Hospital, a tertiary-
level academic hospital that provides services  to a drainage area 
representing 51.9% of the Cape Town metro population. The study 
was approved by the Health Sciences Human Research Ethics 
Committee of the University of Cape Town (REC Ref. 220/2010). 
All patients referred for evaluation of apparent treatment-resistant 
hypertension were included in the analysis. Eligible patients were 
enrolled over a 1-year period beginning in August 2010. Data were 
collected at screening and until the last patient follow-up.
Patients were referred to the hypertension clinic from primary 
and secondary healthcare clinics in the hospital drainage area 
for evaluation of white-coat hypertension or apparent treatment-
resistant hypertension. Patient data were collected at screening, 
and patients with abnormal automated office blood pressures 
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(defined as a mean BP >135/85 mmHg[9]) were fully evaluated 
and followed up at the hypertension clinic. Patient data collected 
included age, gender, BMI, medications used and mean BP. We also 
checked serum potassium, creatinine, glucose, total cholesterol, 
renin and aldosterone and tested for the R563Q mutation of the 
epithelial sodium channel (ENaC).[10] Left ventricular hypertrophy 
(LVH) on the electrocardiograph (ECG) and an abnormal urinary 
albumin/creatinine ratio were used to assess TOD in all patients. 
LVH was defined using either the Sokolow-Lyon or the Cornell 
voltage criteria. A normal urinary albumin/creatinine ratio was 
defined as <3 mg/mmol, microalbuminuria as a urine albumin level 
of 3 - 30 mg/mmol, and macroalbuminuria as >30 mg/mmol. [9] 
The BMI and estimated glomerular filtration rate were calculated 
using the formula weight/height2 and the Modification of Diet in 
Renal Disease equation, respectively.[11] Chronic kidney disease 
was defined according to the Kidney Disease/Improving Global 
Outcomes (KDIGO) guidelines.[12]
Patients underwent screening for secondary causes of hypertension 
based on history, examination and investigations. BP was recorded at 
the screening and follow-up visits and the changes in systolic BP 
and diastolic BP were recorded. BP was measured using a Spacelabs 
automated blood pressure machine, measuring blood pressure at 
2-minute intervals. At screening this was done over a 2-hour period 
and at follow-up over 20 minutes. An average of the last five BP readings 
was recorded for both screening and follow-up visits. Controlled 
BP was defined as a blood pressure of ≤140/90  mmHg. Apparent 
treatment-resistant hypertension was defined as uncontrolled BP 
while using three or more antihypertensive medications, including 
25 mg hydrochlorothiazide daily.
Patients with normal screening blood pressures were referred back 
to their source healthcare facility.
Statistical analysis
Statistical analysis was performed using Microsoft Excel 2010 
(Microsoft, USA). Two-group comparison was done to investigate for 
statistical differences between controlled and uncontrolled patients, 
and between patients with primary hypertension and those with 
secondary causes. The Welch t-test for unpooled variance was used 
for numerical data to minimise sample size discrepancy and non-
Gaussian distribution. Fisher’s exact test was used for categorical data. 
A level of significance of p<0.05 was used.
Selection bias was minimised by including all patients who 
presented for screening, and measurement bias was minimised 
through use of diagnostic criteria and definitions. There was no 
interpretation bias owing to the nature of the study.
Ethical considerations
Patient confidentiality and privacy were upheld for each patient 
according to the outlines in the Declaration of Helsinki.
Results
One hundred and seventy-five patients were enrolled in the study 
(72  males and 103 females, mean age 46.5 years, of whom 27.6% 
were black African, 2.9% white and 69.1% of mixed ancestry). Of 
18 patients who were not on any antihypertensive treatment, 6 had 
a normal BP at initial assessment, translating into a prevalence of 
white-coat hypertension of 3.4%. Of the 175 patients enrolled, 29 
(16.6%) had a normal BP at screening and were discharged back to 
the referring clinic, 36 (20.5%) with a high BP at screening were lost 
to follow-up, and 110 (62.9%) with a high BP were evaluated and 
followed up at the tertiary-level hypertension clinic (Fig. 1). Only 
Normal
screening BP 
n=29
Abnormal BP
(lost to follow-up)
n=36
Control
achieved
n=48
Partial
response
n=28
No response
n=34
Abnormal BP
(formally seen) 
n=110
All patients
screened 
N=175
Fig. 1. Flow chart of the patient sample according to screening BP and BP 
control at follow-up.
Table 1. Gender, age, BMI, BP, LVH and proteinuria in the total patient sample and five patient subgroups
All patients 
(N=175)
Normal 
screening BP 
(n=29)
Controlled 
after follow-
up (n=48)
Uncontrolled 
after follow-up 
(n=62)
Primary 
hypertension 
(n=123)
Secondary 
hypertension 
(n=23)
Males, n 72 15 11 27 63 9
Females, n 103 14 37 35 89 14
Age (years), mean (SD) 46.5 (15.6) 40.6 (15.4) 46.5 (16.9) 49.4 (14.7) 45.8 (15.3) 51.1 (17.2)
BMI (kg/m2), mean (SD) 31.0 (7.2) 30.8 (7.2) 33.4 (8.6) 29.6 (6.0) 31.3 (7.4) 29.2 (5.6)
Screening SBP (mmHg), mean (SD) 148.7 (25.8) 124.0 (9.8) 138.4 (16.7) 160.4 (27.2) 147.1 (24.8) 159.7 (29.9)
Follow-up SBP (mmHg), mean (SD) NA NA 125.2 (9.2) 159.9 (20.3) 143.6 (22.3) 152.2 (31.7)
Change in SBP (mmHg), mean (SD) NA NA –13.2 (18.1) –0.5 (27.0) –6.2 (23.1) –4.9 (31.4)
Screening DBP (mmHg), mean (SD) 89.3 (15.2) 77.2 (8.0) 84.6 (12.7) 94.1 (15.6) 89.1 (14.7) 90.9 (18.5)
Follow-up DBP (mmHg), mean (SD) NA NA 76.4 (7.9) 94.7 (14.1) 86.4 (15.2) 88.7 (12.9)
Change in DBP (mmHg), mean (SD) NA NA –3.8 (13.1) 0.6 (17.9) –3.5 (16.7) –1.1 (15.7)
LVH, n (%) 86 (49.1) 18 (62.1) 20 (41.7) 31 (50.0) 78 (51.3) 8 (34.8)
Microalbuminuria, n (%) 32 (18.3) 0 (0) 8 (16.7) 19 (30.6) 27 (17.8) 5 (21.7)
SBP = systolic blood pressure; DBP = diastolic blood pressure.
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48 (43.6%) of the 110 patients followed up achieved BP control. In 
terms of TOD, 49.1% of patients had evidence of LVH and 18.3% had 
microalbuminuria.
We divided the patients into five groups, viz. normotensive at 
screening, controlled BP at follow-up, uncontrolled BP at follow-up, 
primary hypertension and secondary hypertension. We analysed 
these five groups in terms of gender, age, BMI, screening and follow-
up diastolic and systolic BP, change in BP, and incidence of LVH and 
proteinuria (Table 1). We further compared the groups listed below.
Controlled BP v. uncontrolled BP
In the uncontrolled BP group, 22 of 62 patients had a screening systolic 
BP >160 mmHg. In comparison, the screening systolic BP (p<0.001) 
and diastolic BP (p<0.001) were significantly lower in the controlled 
group of patients. The BMI was significantly different between the 
two groups (p=0.01), being unexpectedly lower in the uncontrolled 
BP group (29.6 kg/m2) than in the controlled BP group (33.4 kg/m2). 
Gender (p=0.01), potassium level (p=0.02) and microalbuminuria 
(p=0.04) differed significantly between the controlled and uncontrolled 
BP groups, with more males, more microalbuminuria and higher 
potassium levels in the uncontrolled BP group.
No differences were found in age (p=0.33), glucose (p=0.44), 
total cholesterol (p=0.83), sodium (p=0.89) or uric acid (p=0.83) 
levels, ethnic distribution (p=0.08), the proportion of patients with 
LVH (p=0.11) or the proportion of those with secondary causes of 
hypertension (p=0.20).
Primary v. secondary hypertension
In total, 23 patients (13.1%) were diagnosed with secondary hyper-
tension. Of these patients, 2 had normal screening blood pressures 
and 5 with hypertension were lost to follow-up. The following causes 
for secondary hypertension were found: ENaC mutations (34.8%), 
primary hyperaldosteronism (21.7%), chronic kidney disease 
(13.0%), renovascular disease (13.0%), thyroid disease (8.7%), aortic 
coarctation (4.3%), and phaeochromocytoma (4.3%).
The screening systolic BP was significantly lower in the group with 
primary hypertension than in the group with secondary hypertension 
(p=0.03), but the diastolic BP was not (p=0.33). Age (p=0.09), 
BMI (p=0.06), and glucose (p=0.42), total cholesterol (p=0.46), 
sodium (p=0.30), potassium (p=0.84) and uric acid (p=0.60) levels 
were also not significantly different. No differences were found in 
gender (p=0.99) or the proportions of patients with LVH (p=0.18), 
microalbuminuria (p=0.58) or BP control (p=0.20).
White-coat and resistant hypertension
Of the 175 patients enrolled, 6 not on antihypertensive treatment and 
23 on antihypertensive treatment had normal BPs at screening. This 
translates to estimated prevalences of white-coat hypertension and 
white-coat effect (higher office BP in hypertensive patients) of 3.4% 
and 13.1%, respectively (overall white-coat effect 16.5%). Twenty-two 
(12.6%) of 175 patients fulfilled the criteria for resistant hypertension 
at the initial assessment. Of these patients, 7 were lost to further 
follow-up and 15 were followed up, of whom only 4 (26.6%) achieved 
BP control after the 12-month follow-up period.
Discussion
Hypertension is a common healthcare challenge in SA, and the 
majority of hypertensive patients can be managed at a primary or 
secondary healthcare level. In our study, 175 patients were enrolled, 
all of whom had been referred for tertiary-level management owing 
to inadequate BP control. Of the patients 16.5% were found to have 
a normal BP at screening, suggesting an underlying white-coat 
effect, although we cannot exclude the possibility that 13.1% of these 
patients who were on antihypertensive treatment improved their 
adherence prior to the initial assessment. Bhatt et al.[13] showed that 
43 of 130 patients were incorrectly diagnosed with apparent resistant 
hypertension when BP measurements obtained by triage staff were 
compared with those obtained by trained physicians using a validated 
BP device on the same day. Interestingly, 62.2% of our patients with 
normal screening BP had evidence of LVH on the ECG, suggesting 
better adherence prior to assessment or that the white-coat effect 
may not be completely benign. A recent meta-analysis by Briasoulis 
et al.[14] concluded that white-coat hypertension is associated with 
increased cardiovascular morbidity and mortality when compared 
with normotensive patients followed up over an 8-year period.[14]
A large proportion of patients (20.6%) were lost to follow-up after 
screening. These patients all warranted further investigations and 
management, but did not attend the follow-up visits for unidentified 
reasons. Patient non-adherence to clinic appointments is an 
important healthcare challenge faced by all clinical disciplines. In 
a 2010 Cochrane review,[15] the authors comment that appointment 
reminder systems increased the proportion of individuals who 
attended for follow-up (odds ratio (OR) 0.41, 95% confidence interval 
(CI) 0.32 - 0.51), and in two small trials these also led to improved 
blood pressure control, the OR favouring intervention (OR  0.54, 
95% CI 0.41 - 0.73). In the SMS-Text Adherence Support (StAR) 
study[16] conducted in primary healthcare clinics in Cape Town, an 
SMS reminder system resulted in only a minor improvement in BP 
(2 mmHg systolic BP), suggesting that other strategies to improve 
adherence are required.
Among the 62.9% of patients who were formally followed up 
at the specialist clinic, a 43.6% rate of BP control was attained 
after a median follow-up period of 232 days. This implies that 
there is a large proportion of patients (56.4% of those referred for 
specialist intervention) who remain uncontrolled despite specialist 
management. Encouragingly, specialist intervention in the sample 
group resulted in mean drops of 13.2 mmHg (range 7.9 - 18.4) in 
systolic BP and 3.8 mmHg (4.4 - 12.0) in diastolic BP. Even in the 
uncontrolled group, there were improvements in BP, which are 
beneficial. A recent assessment of drug levels for amlodipine and 
angiotensin-converting enzyme inhibitors in our hypertension clinic 
suggests that 20% of patients are non-adherent at any one visit.(17) 
Interventions to improve patient adherence, such as reducing daily 
doses, appear to be effective, although there is less evidence of an 
effect on BP reduction.[18]
There was a high prevalence of TOD in our patient sample, with 
49.1% having evidence of LVH and 18.3% having microalbuminuria. A 
recent systematic review of 40 444 treated and untreated hypertensive 
patients found the prevalence of LVH on ECG to be 18%.[19] Our 
average prevalence of 49.1% is far higher, suggesting either that our 
population is inherently at higher risk of LVH or, more plausibly, 
that there are a greater number of patients with undetected and 
uncontrolled hypertension in our population. National hypertension 
work groups and guidelines have advocated for a long time that 
more resources be allocated to the early detection and management 
of hypertension in SA communities to prevent the onset of TOD. 
This would logically translate into significant cost savings for the 
state, in terms of less expenditure on renal replacement programmes, 
stroke care and interventional cardiology for ischaemic heart 
disease. However, this remains a major healthcare challenge, and will 
necessitate application of greater impetus to hypertension screening 
and education programmes across all communities.
Our study also aimed to identify key differences between patients 
who attained BP control and those who did not. In comparison with 
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the controlled group, the uncontrolled group was older, comprised 
more males, had a higher systolic and diastolic BP at screening, and 
comprised more patients with secondary causes and TOD.
Contrary to current thinking, we found that a low BMI was associated 
with poor BP control. We know from large Asian and African cohorts[20] 
that BP has a non-linear relationship to BMI in females and that there is 
a cut-off of 21 kg/m2 below which the relationship is unclear. However, 
this phenomenon is not found in males and is therefore difficult to 
explain in our patients. A higher serum potassium level was also found 
in the uncontrolled hypertension group compared with the controlled 
group (4.3 mmol/L v. 4.0 mmol/L), but the difference is small and may 
just be a chance finding.
Our study also looked at the number of patients diagnosed 
with secondary hypertension. Of the 175 patients referred to our 
hypertension clinic, 13.1% were found to have secondary causes of 
hypertension. This is higher than the traditionally quoted prevalence 
from community-based studies and may be explained by the selective 
nature of our sample. We also included ENaC mutations as a secondary 
cause, and this test would not have been routinely performed in other 
studies. When compared with patients with primary or essential 
hypertension, the patients with secondary hypertension were older 
and had higher screening and follow-up systolic and diastolic BPs.
The R563Q β-ENaC mutation and primary hyperaldosteronism 
together were responsible for >50% of cases of secondary hypertension 
in our study. This reaffirms the high prevalence of both these 
conditions found in previous studies at our hypertension clinic.[10,21] 
The R563Q β-ENaC mutation and primary hyperaldosteronism 
are currently treated with good success with amiloride and 
spironolactone, respectively, emphasising the importance of referring 
patients with apparent treatment-resistant hypertension to a specialist 
hypertension clinic.
The estimated prevalence of resistant hypertension in our study 
was 15%. This is lower than the prevalence of resistant hypertension 
of between 25% and 35% from large clinical studies in other 
countries,[22-24] but higher than the 8.2% prevalence detected in a 
recent Italian study of 1 177 patients.[25] However, only 4 of the 15 
resistant patients followed up in our study achieved BP control, 
suggesting that these patients are challenging to treat.
Study limitations
Limitations to the study include its descriptive nature, the assumption 
that patients are completely adherent to treatment, and the large 
difference in the sizes of the primary and secondary hypertension 
comparator groups.
Conclusion
Hypertension is a major contributor to the disease burden in SA, and 
not all patients are suitable for management at a primary or secondary 
healthcare level. Referral to a specialist hypertension clinic was found 
to have a favourable effect on hypertension management, with a 43.6% 
control rate in patients previously uncontrolled at referring facilities. 
However, this level of control is not ideal. Significant challenges 
therefore remain, and new strategies need to be developed to deal 
with them. There are very few specialist hypertension clinics in SA, 
and these tend to be under-resourced. Further research is required 
to determine whether specialist intervention in poorly controlled 
hypertensive patients improves long-term outcome. Another positive 
finding of this study is that the use of prescreening automated BP 
monitoring at our hypertension clinic reduced the need for full 
evaluation and follow-up in 16.5% of referred patients. Both resistant 
hypertension and secondary hypertension are prevalent in patients 
with poor BP control referred to a specialist hypertension clinic. 
The rate of complications of inadequate BP control in terms of TOD 
was found to be high, so we recommend that patients with apparent 
resistant hypertension be referred timeously to tertiary centres for 
specialist intervention.
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